Skip to main content
LFCR logo

LFCR · Lifecore Biomedical, Inc. \De\

$4.58 -0.06 (-1.29%) At close · Jul 22
Market Cap
$171.79M
Shares
37.51M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-07-15 Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on July 13, 2026, Lifecore granted a restricted stock unit (“RSU”) award

2026-06-15 Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated

2026-06-02 Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn., June 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc.

2026-05-21 Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference

CHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the William Blair 46 th Annual Growth Stock

2026-05-12 Lifecore Biomedical to Participate at CDMO Live Europe

CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at CDMO Live Europe.

2026-05-06 Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update

-- Reaffirms 2026 Guidance -- -- Signed Three New Commercial Site Transfer Programs in First Quarter 2026 -- -- Cost Containment Initiatives Continue to Drive Down Expenses -- Conference Call Today at 8:00am ET CHASKA, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc.

2026-04-29 Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026

Webcast Scheduled for Wednesday, May 6 at 8:00 a.m. Eastern CHASKA, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report

2026-04-22 Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on April 20, 2026, Lifecore granted a restricted stock unit (“RSU”)

2026-04-08 Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit

CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 12 th Annual American Biomanufacturing

2026-03-26 Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on March 25, 2026, Lifecore granted a restricted stock unit (“RSU”)

2026-03-26 Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive

Past events

Source: https://ir.lifecore.com/

Key facts CIK 1005286 CUSIP 514766104 13F (30d) 12 filings 12 filers Visit website Investor relations